AIDS Alert Archives – August 1, 2009
August 1, 2009
View Issues
-
CDC researchers find that too many people are diagnosed late
Too many Americans with HIV infection continue to be tested late in their disease, despite decades of HIV awareness, prevention, and testing campaigns and efforts. -
NY program provides HIV interventions for inmates
A New York AIDS service organization (ASO) has found that a good HIV prevention program for people who were incarcerated in state prisons involves a multi-step program that includes health/HIV education, finding them a place to live, finding them a job, and following up with community support. -
HIV prevention program for ex-offenders succeeds
Before HIV educators can hope to change HIV risk behavior among high-risk ex-offenders, they need to help these men and women change their attitudes about their lives in general, an expert says. -
The 'Safety Counts' HIV prevention model
Investigators are using an adaptation of the Safety Counts model for HIV prevention to evaluate the impact of HIV education, hepatitis education, and a substance abuse intervention on people who are at high-risk for HIV infection in New York. -
Abstract & Commentary: Lumbar puncture in HIV patients with syphilis
Eligible subjects in this study included all patients with concurrent HIV infection and syphilis in a prospective cohort who had no neurologic symptoms at time of lumbar puncture. -
Young and untested, HIV spread continues
In 2007 only 12.9% of high school students overall and 22.3% of students who ever had sexual intercourse had been tested for HIV, the Centers for Disease Control and Prevention reports. -
FDA Notifications
On July 8, 2009, FDA granted approval to raltegravir (ISENTRESS) for the treatment of HIV-1 infection in treatment-naïve patients. An integrase inhibitor made by Merck & Co, the recommended dose for treatment-naïve adult patients is raltegravir 400 mg twice daily, with or without food.